To explore the mechanisms underlying deregulation of the Pyrin inflammasome in FMF patients, we decided to assess the efficacy of staurosporine (a potent PKC superfamily inhibitor targeting PKN1/2; Davis et al, 2011) to trigger IL‐1β release in primary monocytes from HD or FMF patients. The gene discussed is MEFV; the disease is Huntington disease.